{"id":8165,"date":"2020-12-10T20:30:56","date_gmt":"2020-12-10T20:30:56","guid":{"rendered":"https:\/\/medicalcriteria.com\/web\/?p=8165"},"modified":"2026-01-07T18:49:42","modified_gmt":"2026-01-07T18:49:42","slug":"myelodysplasia","status":"publish","type":"post","link":"https:\/\/medicalcriteria.com\/web\/myelodysplasia\/","title":{"rendered":"Diagnostic Criteria for Myeloid Neoplasms with Myelodysplasia"},"content":{"rendered":"<div class=\"99c380e4b4a7b96c35d7ddf7dcb434e8\" data-index=\"1\" style=\"float: none; margin:0px 0 0px 0; text-align:center;\">\n<script async src=\"https:\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js\"><\/script>\r\n<!-- MC 2019- Horizontal -->\r\n<ins class=\"adsbygoogle\"\r\n     style=\"display:block\"\r\n     data-ad-client=\"ca-pub-0127150553352455\"\r\n     data-ad-slot=\"3806776041\"\r\n     data-ad-format=\"auto\"\r\n     data-full-width-responsive=\"true\"><\/ins>\r\n<script>\r\n     (adsbygoogle = window.adsbygoogle || []).push({});\r\n<\/script>\n<\/div>\n<p>Myelodysplastic syndromes (MDS) are myeloid neoplasms characterized by clonal proliferation of hematopoietic stem cells, recurrent genetic abnormalities, myelodysplasia, ineffective hematopoiesis, peripheral-blood cytopenia, and a high risk of evolution to acute myeloid\u00a0leukemia (AML). <!--more--><\/p>\n<p><strong>Diagnostic Criteria for Myeloid Neoplasms with Myelodysplasia and Precursor Conditions for Myelodysplastic s<\/strong><strong>yndromes red 5px solid(MDS)<\/strong><\/p>\n<table style=\"border-collapse: collapse; width: 100%;\" border=\"1\">\n<tbody>\n<tr style=\"height: 24px;\">\n<td style=\"width: 23.4589%; height: 24px;\"><strong>Disorder<\/strong><\/td>\n<td style=\"width: 76.5411%; height: 24px;\"><strong>Diagnostic Criteria<\/strong><\/td>\n<\/tr>\n<tr style=\"height: 24px;\">\n<td style=\"width: 100%; height: 24px;\" colspan=\"2\"><strong>Myeloid neoplasms with myelodysplasia<\/strong><\/td>\n<\/tr>\n<tr style=\"height: 240px;\">\n<td style=\"width: 23.4589%; height: 240px;\">MDS<\/td>\n<td style=\"width: 76.5411%; height: 240px;\">Persistent cytopenia in one or more peripheral-blood cell lineages and morphologic dysplasia (\u226510% dysplastic cells) in one or more bone marrow cell lineages; on the basis of morphologic and cytogenetic abnormalities, MDS are categorized into the following subtypes:<br \/>\nMDS with single-lineage dysplasia<br \/>\nMDS with multilineage dysplasia<br \/>\nMDS with ring sideroblasts and single-lineage dysplasia or multilineage dysplasia<br \/>\nMDS with isolated del(5q)<br \/>\nMDS with excess blasts type 1 or type 2<br \/>\nMDS, unclassifiable<\/td>\n<\/tr>\n<tr style=\"height: 192px;\">\n<td style=\"width: 23.4589%; height: 192px;\">Myelodysplastic\u2013myeloproliferative neoplasms<\/td>\n<td style=\"width: 76.5411%; height: 192px;\">Myeloid neoplasms with clinical, laboratory, and morphologic features that overlap those of MDS and myeloproliferative neoplasms; myelodysplastic\u2013myeloproliferative neoplasms are divided into the following subtypes:<br \/>\nChronic myelomonocytic leukemia<br \/>\nBCR-ABL1\u2013negative atypical chronic myeloid leukemia<br \/>\nMyelodysplastic\u2013myeloproliferative neoplasm with ring sideroblasts and thrombocytosis<br \/>\nJuvenile myelomonocytic leukemia<\/td>\n<\/tr>\n<tr style=\"height: 48px;\">\n<td style=\"width: 23.4589%; height: 48px;\">Therapy-related myeloid neoplasms<\/td>\n<td style=\"width: 76.5411%; height: 48px;\">MDS, myelodysplastic\u2013myeloproliferative neoplasms, and acute myeloid leukemia that occur as late complications of chemotherapy or radiotherapy<\/td>\n<\/tr>\n<tr style=\"height: 24px;\">\n<td style=\"width: 100%; height: 24px;\" colspan=\"2\"><strong>MDS precursor conditions<\/strong><\/td>\n<\/tr>\n<tr style=\"height: 72px;\">\n<td style=\"width: 23.4589%; height: 72px;\">Clonal Hematopoiesis of Indeterminate Potential (CHIP)<\/td>\n<td style=\"width: 76.5411%; height: 72px;\">Normal peripheral-blood cell counts with a somatic mutation, at a variant allele frequency of at least 2%, in a gene that is recurrently mutated in myeloid neoplasms\u2021<\/td>\n<\/tr>\n<tr style=\"height: 144px;\">\n<td style=\"width: 23.4589%; height: 144px;\">Clonal Cytopenia of Undetermined Significance (CCUS)<\/td>\n<td style=\"width: 76.5411%; height: 144px;\">Unexplained cytopenia in one or more peripheral-blood cell lineages; a somatic mutation, at a variant allele frequency of at least 20%, in one or more genes that are recurrently mutated in myeloid neoplasms; and insufficient WHO criteria for a diagnosis of MDS, essentially because of lack of overt dysplasia (&lt;10% dysplastic cells in any bone marrow\u00a0cell lineage), excess blasts, and MDS-defining chromosomal abnor-malities \u00a7<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>\u2021 Persons with CHIP may have increased values for red-cell distribution width.<br \/>\n\u00a7 Although a variant allele frequency of at least 2% was initially suggested for the diagnosis of CCUS, the available evidence indicates that a higher cutoff point (20%) should be used to identify clinically significant clonality.<\/p>\n<p>&nbsp;<\/p>\n<p><strong>References:<\/strong><\/p>\n<ol>\n<li>Cazzola M. Myelodysplastic Syndromes. N Engl J Med. 2020 Oct 1;383(14):1358-1374. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/32997910\/\" target=\"_blank\" rel=\"noopener noreferrer\">[Medline]<\/a><\/li>\n<li>Shreve J, Nazha A. Novel Prognostic Models for Myelodysplastic Syndromes. Hematol Oncol Clin North Am. 2020 Apr;34(2):369-378. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/32089216\/\" target=\"_blank\" rel=\"noopener noreferrer\">[Medline]<\/a><\/li>\n<\/ol>\n<p>&nbsp;<\/p>\n<p>Created Nov 26, 2020.<\/p>\n\n<div style=\"font-size: 0px; height: 0px; line-height: 0px; margin: 0; padding: 0; clear: both;\"><\/div>","protected":false},"excerpt":{"rendered":"<p>Sorry, this entry is only available in Espa\u00f1ol.<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"no","_lmt_disable":"no","_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":""},"categories":[171],"tags":[16,15,14,13,2289,2288,2286,2284,2287,2285],"class_list":["post-8165","post","type-post","status-publish","format-standard","hentry","category-hematology","tag-criteria","tag-criterios","tag-diagnostic","tag-diagnostico","tag-mielodisplasia","tag-mieloides","tag-myelodysplasia","tag-myeloid","tag-neoplasias","tag-neoplasms"],"modified_by":"Guillermo Firman","_links":{"self":[{"href":"https:\/\/medicalcriteria.com\/web\/wp-json\/wp\/v2\/posts\/8165","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medicalcriteria.com\/web\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medicalcriteria.com\/web\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medicalcriteria.com\/web\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/medicalcriteria.com\/web\/wp-json\/wp\/v2\/comments?post=8165"}],"version-history":[{"count":14,"href":"https:\/\/medicalcriteria.com\/web\/wp-json\/wp\/v2\/posts\/8165\/revisions"}],"predecessor-version":[{"id":9441,"href":"https:\/\/medicalcriteria.com\/web\/wp-json\/wp\/v2\/posts\/8165\/revisions\/9441"}],"wp:attachment":[{"href":"https:\/\/medicalcriteria.com\/web\/wp-json\/wp\/v2\/media?parent=8165"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medicalcriteria.com\/web\/wp-json\/wp\/v2\/categories?post=8165"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medicalcriteria.com\/web\/wp-json\/wp\/v2\/tags?post=8165"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}